Authors:
PUNT CJA
BURGHOUTS JTM
KATEMAN I
CROLES JJ
KAMM YL
WAGENER DJT
Citation: Cja. Punt et al., DOUBLE ALTERNATE MODULATION OF HIGH-DOSE 5-FLUOROURACIL BY INTERFERON-ALPHA-2B AND PHOSPHONACETYL-L-ASPARTIC ACID IN PATIENTS WITH ADVANCEDCOLORECTAL-CANCER, Oncology Reports, 1(4), 1994, pp. 755-757
Authors:
HOFS HP
WAGENER DJT
DEVALKBAKKER V
VANRENNES H
OTTENHEIJM HCJ
DEGRIP WJ
Citation: Hp. Hofs et al., CONCENTRATION AND SEQUENCE-DEPENDENT SYNERGISM OF ETHYLDESHYDROXY-SPARSOMYCIN IN COMBINATION WITH ANTITUMOR AGENTS, Anti-cancer drugs, 5(1), 1994, pp. 35-42
Citation: Djt. Wagener et al., CURRENT STATUS AND FUTURE-DIRECTIONS IN THE PERIOPERATIVE TREATMENT OF PANCREATIC-CANCER, Annals of oncology, 5, 1994, pp. 190000087-190000090
Authors:
KAMM YJL
RIETJENS IMCM
VERVOORT J
HEERSCHAP A
ROSENBUSCH G
HOFS HP
WAGENER DJT
Citation: Yjl. Kamm et al., EFFECT OF MODULATORS ON 5-FLUOROURACIL METABOLITE PATTERNS IN MURINE COLON-CARCINOMA DETERMINED BY IN-VITRO F-19 NUCLEAR-MAGNETIC-RESONANCESPECTROSCOPY, Cancer research, 54(16), 1994, pp. 4321-4326
Authors:
ROELOFS EJM
WAGENER DJT
CONROY T
WILS J
BURGHOUTS JT
FICKERS M
DEGRAEFF A
LALISANG F
PAILLOT B
Citation: Ejm. Roelofs et al., PHASE-II STUDY OF SEQUENTIAL HIGH-DOSE METHOTREXATE (MTX) AND 5-FLUOROURACIL (F) ALTERNATED WITH EPIRUBICIN (E) AND CISPLATIN (P) [FEMTX-P]IN ADVANCED GASTRIC-CANCER, Annals of oncology, 4(5), 1993, pp. 426-428
Citation: J. Wils et Djt. Wagener, COMBINED MODALITY ADJUVANT TREATMENT OF HIGH-RISK RECTAL-CANCER - A TREATMENT OF CHOICE OR A CHOICE OF TREATMENT, Annals of oncology, 3(3), 1992, pp. 197-199